

Sanofi-aventis announces Changes to Executive Committee

Paris, France – November 2, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today a number of changes to its Executive Committee. In a message to employees, Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, detailed the new appointments and his new management team.

In order to manage the Group's new business activities beyond pharmaceuticals, **Hanspeter SPEK** is appointed **President, Global Operations**. He was previously Executive Vice President, Pharmaceutical Operations.

Given the strategic importance of the Transforming R&D program, **Marc CLUZEL** is appointed **Executive Vice President, Research & Development**. He was previously Senior Vice President, Research & Development.

Finally, due to the essential role of Sanofi Pasteur, the vaccines worldwide leader, **Wayne PISANO**, **Senior Vice President, Vaccines**, joins the Group's Executive Committee.

As from today, the Executive Committee, chaired by Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, meets twice a month and comprises the following members :

- | | |
|---------------------|--|
| - Marc CLUZEL, | Executive Vice President, Research & Development |
| - Jérôme CONTAMINE, | Executive Vice President, Chief Financial Officer |
| - Laurence DEBROUX, | Senior Vice President, Chief Strategic Officer |
| - Karen LINEHAN, | Senior Vice President, Legal Affairs and General Counsel |
| - Philippe LUSCAN, | Senior Vice President, Industrial Affairs |
| - Wayne PISANO, | Senior Vice President, Vaccines |
| - Roberto PUCCI, | Senior Vice President, Human Resources |
| - Hanspeter SPEK, | President, Global Operations. |

Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis declared: “ *I am extremely pleased to work with this international team who gathers competence, energy and experience to transform sanofi-aventis into a global diversified healthcare leader*”.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).